outperform price
amid enterpris continu
deliv
today bring anoth data point show strength
cvss enterpris model result show benefit
covid-rel consum stock up lower util
well continu integr synergi look forward
higher degre confid end
toward higher end guidanc given
out-performance despit updat higher util
recess healthcar segment new outlook
reflect lower commerci enrol higher medicaid
enrol look beyond lower
estim given continu post-covid util trend
well enrol shift impact recess
prescript front end result howev despit
macro-driven chang underli busi perform
well still track deliv dd ep growth
delev low given factor
reiter outperform rate share rais
price target forward ebitda
pleas see confer call note
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
april retail comp y/i vs y/i march
pharmaci sale y/i vs march
pharmaci adjust prescript volum y/i vs march
fe sale april vs march
increas basket size off-set reduc store traffic
pharmaci servic total claim process y/i vs march
chang april script claim process volum vs march driven revers demand pull-
forward lower physician visit
telehealth deliv home seen substanti growth util
shelter place remov move person market
store reduc front end hour oper
pharmaci reduct hour
health benefit medicaid commerci dynam
reduct utilizationpharmaci flat inpati outpati
lab/radiology/hom health
pre-author hcb saw declin
new therapi start due fewer physician visit
mbr could lowest year see pressur medicaid mbr
see increas medicaid enrol april
medicaid affect longer flu season unusu high claim
expect improv enrol state cut rate yet
saw rel younger healthi medicaid member expect skew
oper expens due medicaid onboard illinicar still see strand
cost aetna divestitur
yoy declin small group continu push make aso
expect declin latter half year
see declin commerci book april
pbm saw outsiz growth rel full year prior covid
pharmaci see less impact home deliveri see strength
new therapi start april includ acut event mainten
new start antibiot
signific increas covid oper expens increas compar
retent book see retent rate
rfp activ consist theyv seen histor
quarterli cadenc like vari histor
underli sale perform ex covid still
fe repres enterpris revenu
earli view sale improv
see slight slowdown store convers
capabl telehealth minuteclin everi state oper
test see big util brick mortar center
integr part go market
expect signific uptick individu want get flu shot local pharmaci
rather doctor offic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
potenti elev govern scrutini drug price transpar neg impact long-
potenti on-line competit amazon erod front end comp margin us
continu reimburs pressur us eu hit ultim lead total margin
laboratori corp america
articl articl
time dissemin may pm et
analyst elizabeth anderson amato michael newshel primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
